Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 13/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9904163 | 0.80 | ALDH1A1 (0.53) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL15033699 | 0.79 | ADRB1 (0.36) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9899693 | 0.79 | MAPT (0.46) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9899784 | 0.78 | S100B (0.36) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9939965 | 0.78 | MAPT (0.36) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL9899721 | 0.77 | KMT2A (0.53) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL21761895 | 0.76 | MAPT (0.59) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL16181915 | 0.76 | NR1H2 (0.36) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL10035934 | 0.74 | POLB (0.59) | MAPTKMT2AALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL9898192 | 0.74 | MAPT (0.43) | MAPTKMT2AALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649052-B1 | 2-AMINOBENZIMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INT (DE) | 2014-10-22 | — | — | EP | disclosed |
| EP-2649052-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | Boehringer Ingelheim International GmbH (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-8466186-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120309738-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-06 | — | — | US | disclosed |
| WO-2012076672-A1 | 2 -AMINOBENZ IMIDAZOLE DERIVATIVES USEFUL IN THE TREATMENT OF INFLAMMATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309738-A1 | NOVEL COMPOUNDS | PTGER1, PTGS1, PTGES | MAPT 4308/4885KMT2A 3417/4885ALDH1A1 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.